Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Shares of Landos Biopharma, Inc. LABP rose sharply during Monday’s session following acquisition news.

AbbVie Inc. ABBV and Landos Biopharma, reported a definitive agreement under which AbbVie will acquire Landos.

Landos Biopharma shares jumped 171.2% to $21.70 on Monday.

Here are some other stocks moving in today's mid-day session.

Gainers

• Next.e.GO N.V. EGOX shares jumped 85.8% to $0.0730 after falling around 22% on Friday.
• Altamira Therapeutics Ltd. CYTO shares climbed 70.1% to $2.9255 after the company announced a collaboration with Univercells Group on nanoparticle-delivered mRNA vaccines.
• MicroAlgo Inc. MLGO climbed 34.3% to $5.40 after declining around 5% on Friday.
• XTL Biopharmaceuticals Ltd. XTLB gained 32.4% to $3.4690. XTL Biopharmaceuticals recently entered into a binding term sheet to acquire all of the issued and outstanding share capital of Social Proxy.
• Nkarta, Inc. NKTX gained 23.3% to $11.00 after the company priced $240 million underwritten offering.
• Target Hospitality Corp. TH jumped 21.3% to $10.82 after the company received a buyout offer from TDR Capital.
• Swvl Holdings Corp. SWVL rose 21.2% to $11.26.
• Brainstorm Cell Therapeutics Inc. BCLI surged 21% to $0.6949.
• Lucid Group, Inc. LCID jumped 18.7% to $3.29 after the company announced a $1 billion investment by an affiliate of PIF.
• Sagimet Biosciences Inc. SGMT rose 16.9% to $5.27 after the company reported FY results and announced the appointment of Tim Walbert and Paul Hoelscher to its Board of Director.
• Ocugen, Inc. OCGN jumped 16.4% to $1.9101. The Third Circuit Court of Appeals recently upheld the decision of the Eastern District of Pennsylvania to dismiss with prejudice the consolidated securities class action lawsuits against Ocugen.
• Flora Growth Corp. FLGC shares gained 15.2% to $1.8206 after surging around 34% on Friday.
• Forge Global Holdings, Inc. FRGE shares gained 14.5% to $2.67 after gaining 13% on Friday.
• Cipher Mining Inc. CIFR jumped 14.1% to $5.27.
• GoodRx Holdings, Inc. GDRX rose 13.5% to $7.44 after Wells Fargo upgraded the stock from Equal-Weight to Overweight and announced a $10 price target.
• Neuronetics, Inc. STIM climbed 13.5% to $4.80. NeuroStar® Advanced Therapy received FDA clearance as a first-line add-on treatment for adolescents with depression.
• Lichen China Limited LICN rose 12.6% to $1.16. Lichen China announced the launch of AI-powered software - Lichen AI Robot, which was developed on GPT-based technology.
• UroGen Pharma Ltd. URGN rose 11.1% to $17.51.
• Cazoo Group Ltd CZOO gained 11% to $4.12 after declining around 21% on Friday.
• Salarius Pharmaceuticals, Inc. SLRX rose 10.5% to $0.6849 following fourth-quarter results.
• MicroStrategy Incorporated MSTR gained 10.3% to $1,680.00 amid strength in Bitcoin.
• Masimo Corporation MASI jumped 9.5% to $147.72 after the company announced it has authorized management to evaluate a proposed separation of its consumer business.
• Foot Locker, Inc. FL shares rose 8.4% to $26.45 after Evercore ISI Group upgraded the stock from In-Line to Outperform and raised its price target from $28 to $32.
• GameStop Corp. GME gained 8.2% to $14.17.
• Esperion Therapeutics, Inc. ESPR gained 6.6% to $2.40 after the FDA approved broad labels for NEXLETOL and NEXLIZET to prevent heart attacks and cardiovascular procedures, regardless of statin use.
• Micron Technology, Inc. MU climbed 5.1% to $115.81.

Losers

• Sintx Technologies, Inc. SINT shares fell 49.1% to $0.0471 after the company announced pricing of a $1.3 million public offering of common stock.
• Akanda Corp. AKAN fell 38.1% to $0.1507 after the company announced pricing of underwritten public offering.
• Fisker Inc. FSR dipped 28.1% to $0.0897 after the company announced it received notice from the large automaker with which the company had been in negotiations for a potential transaction that the automaker terminated the negotiations.
• Australian Oilseeds Holdings Limited COOT fell 25.4% to $1.85 after falling over 22% on Friday.
• Vimeo, Inc. VMEO fell 26% to $3.98.
• Aurora Mobile Limited JG dipped 18.8% to $2.8428. Aurora Mobile announced plans to use Moonshot AI large language model in its AI bot creation platform, GPTBots.AI.
• Invivyd, Inc. IVVD fell 18.3% to $3.56. Invivyd shares jumped 41% on Friday after the company announced that PEMGARDA received emergency use authorization from the FDA for the pre-exposure prophylaxis of COVID-19.
• Li-Cycle Holdings Corp. LICY dipped 18.7% to $0.9181.
• Aehr Test Systems AEHR fell 18.1% to $12.01 after the company reported preliminary third-quarter and FY24 adjusted EPS and revenue results below estimates.
• Bitcoin Depot Inc. BTM fell 17.1% to $2.2216 following weak quarterly sales.
• Invivyd, Inc. IVVD declined 16.7% to $3.63.
• Sonder Holdings Inc. SOND fell 16.3% to $3.29.
• Jowell Global Ltd. JWEL fell 16.1% to $1.36.
• BYND Cannasoft Enterprises Inc. BCAN fell 15.4% to $2.12 after dipping 31% on Friday.
• Canopy Growth Corporation CGC fell 13.1% to $6.68. The German government recently approved legislation which legalizes the possession and cultivation of cannabis beginning April 1.
• Compass Minerals International, Inc. CMP declined 13.1% to $15.25. US Forest Service halted contract with Compass Minerals for 2024 Fire Season due to safety concerns.
• Yiren Digital Ltd. YRD fell 12% to $4.46.
• Dyne Therapeutics, Inc. DYN dipped 11.8% to $24.90 after the company announced a CEO transition.
• Open Lending Corporation LPRO fell 10.3% to $6.41. Open Lending named Chuck Jehl as COO and Interim CEO.
• Ontrak, Inc. OTRK fell 10% to $0.3531 after jumping around 50% on Friday.
• Laser Photonics Corporation LASE shares fell 9.2% to $1.68 after dipping around 9% on Friday. Laser Photonics, last week, announced a distribution agreement with Incredible Supply & Logistics (ISL) for its military and industrial laser solutions.
• OKYO Pharma Limited OKYO shares fell 7.5% to $1.42 after falling around 13% on Friday. OKYO Pharma, last week, announced additional key findings from analyses of the clinical data set from the 240-patient Phase 2 trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED).

Now Read This: Bitcoin Surpasses $67,000; Internet Computer Emerges As Top Gainer